Quetiapine
- Generic Name
- Quetiapine
- Brand Names
- Seroquel
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25N3O2S
- CAS Number
- 111974-69-7
- Unique Ingredient Identifier
- BGL0JSY5SI
- Background
Initially approved by the FDA in 1997, quetiapine is a second-generation atypical antipsychotic used in schizophrenia, major depression, and bipolar disorder. Quetiapine demonstrates a high level of therapeutic efficacy and low risk of adverse effects during long-term treatment. It is well-tolerated and a suitable option for some patients with high sensitivity to other drugs, such as Clozapine and Olanzapine.
- Indication
Quetiapine is used in the symptomatic treatment of schizophrenia. In addition, it may be used for the management of acute manic or mixed episodes in patients with bipolar I disorder, as a monotherapy or combined with other drugs. It may be used to manage depressive episodes in bipolar disorder. In addition to the above indications, quetiapine is used in combination with antidepressant drugs for the treatment of major depression.
Some off-label uses for this drug include the management of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and psychosis associated with Parkinson's disease.
- Associated Conditions
- Bipolar 1 Disorder, Depressive Episodes, Generalized Anxiety Disorder, Major Depressive Disorder (MDD), Mixed manic depressive episode, Post Traumatic Stress Disorder (PTSD), Psychosis, Schizophrenia, Acute Manic episode
- Associated Therapies
- -
Efficacy of Quetiapine in Generalised Social Anxiety Disorder
- Conditions
- Social Anxiety Disorder
- First Posted Date
- 2006-03-15
- Last Posted Date
- 2011-01-27
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 50
- Registration Number
- NCT00302770
- Locations
- 🇳🇱
Research Site, Utrecht, Netherlands
High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder
- First Posted Date
- 2006-03-01
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- Manhattan Psychiatric Center
- Target Recruit Count
- 60
- Registration Number
- NCT00297947
- Locations
- 🇺🇸
Manhattan Psychiatric Center, New York, New York, United States
🇺🇸Nathan Kline Institute for Psychiatric Research, Orangeburg, New York, United States
Quetiapine Augmentation for Treatment-resistant PTSD
- Conditions
- Combat DisordersStress Disorders, Post-Traumatic
- Interventions
- First Posted Date
- 2006-02-15
- Last Posted Date
- 2019-10-16
- Lead Sponsor
- VA Office of Research and Development
- Target Recruit Count
- 124
- Registration Number
- NCT00292370
- Locations
- 🇺🇸
Tuscaloosa VAMC, Tuscaloosa, Alabama, United States
🇺🇸Ralph H. Johnson, Charleston, South Carolina, United States
🇺🇸Birmingham VA Medical Center, Birmingham, Alabama, United States
Study of Quetiapine Monotherapy in Ambulatory Bipolar Spectrum Disorder With Moderate-to-Severe Hypomanic Symptoms or Mild Manic Symptoms
- Conditions
- Bipolar Disorder
- First Posted Date
- 2006-01-16
- Last Posted Date
- 2009-03-13
- Lead Sponsor
- Lindner Center of HOPE
- Target Recruit Count
- 40
- Registration Number
- NCT00277667
- Locations
- 🇺🇸
University of Cincinnati Medical Center, Cincinnati, Ohio, United States
Movement Disorders Caused by Antipsychotic Drugs in Older Patients
- Conditions
- Dyskinesia, Drug-Induced
- First Posted Date
- 2005-11-21
- Last Posted Date
- 2013-06-06
- Lead Sponsor
- University of California, San Diego
- Target Recruit Count
- 250
- Registration Number
- NCT00255879
- Locations
- 🇺🇸
University of California, San Diego Division of Geriatric Psychiatry, San Diego, California, United States
Fast Titration Of Quetiapine Versus Currently Approved Titration
- Conditions
- Psychotic Disorders
- First Posted Date
- 2005-11-17
- Last Posted Date
- 2011-01-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 150
- Registration Number
- NCT00254813
- Locations
- 🇳🇴
Research Site, Ålesund, Norway
Venlafaxine Augmentation in Treatment Resistant Depression
- First Posted Date
- 2005-11-15
- Last Posted Date
- 2015-04-08
- Lead Sponsor
- Max-Planck-Institute of Psychiatry
- Target Recruit Count
- 126
- Registration Number
- NCT00253266
- Locations
- 🇩🇪
Max Planck Institute of Psychiatry, Munich, Bavaria, Germany
Quetiapine (Seroquel) Maintenance Treatment in Early Onset Bipolar Spectrum Disorders
- Conditions
- Bipolar Disorder
- First Posted Date
- 2005-11-11
- Last Posted Date
- 2008-06-04
- Lead Sponsor
- Mood Disorders Center of Ottawa
- Target Recruit Count
- 100
- Registration Number
- NCT00252226
- Locations
- 🇨🇦
Mood Disorders Center of Ottawa, Ottawa, Ontario, Canada
Effectiveness of Atypical Versus Conventional Antipsychotics in Treating Schizophrenia
- Conditions
- Schizophrenia
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2014-06-06
- Lead Sponsor
- Yale University
- Registration Number
- NCT00237861
Quetiapine Treatment for Post-Traumatic Stress Disorder (PTSD)
- First Posted Date
- 2005-10-12
- Last Posted Date
- 2008-02-21
- Lead Sponsor
- Ralph H. Johnson VA Medical Center
- Target Recruit Count
- 80
- Registration Number
- NCT00237393
- Locations
- 🇺🇸
NM VA Healthcare System, Albuquerque, New Mexico, United States
🇺🇸Ralph H. Johnson VAMC, Charleston, South Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.